olanzapine therapy
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
May 1, 2006 → Sep 1, 2007
NCT ID
NCT00324051About olanzapine therapy
olanzapine therapy is a approved stage product being developed by Eli Lilly for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00324051. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00324051 | Approved | Completed |
Competing Products
20 competing products in Schizophrenia